OAB0205 Vesatolimod, a toll-like receptor 7 (TLR7) agonist, induces dose-dependent immune responses in HIV controllersOral Abstract SessionB40
OAB0302 Analysis of protocol defined virologic failure through week 48 from a phase 2 trial (P011) of islatravir and doravirine in treatment-naïve adults with HIV-1 infectionOral Abstract SessionB30
OAB0303 Adherence and factors associated with virologic success in HIV-1 infected adults with tuberculosis receiving raltegravir or efavirenz in the ANRS 12300 Reflate TB2 trialOral Abstract SessionB30
OAB0304 Reducing ART to less than 3-ARV regimen linked to increased systemic inflammationOral Abstract SessionB32
OAB0305 Islatravir safety analysis through week 48 from a phase 2 trial in treatment naïve adults with HIV-1 infectionOral Abstract SessionB66
OAB0402 Dolutegravir- versus low-dose Efavirenz-based regimen for the initial treatment of HIV-1 infection in Cameroon: Week 96 results of the ANRS 12313 ' NAMSAL trialOral Abstract SessionB30
OAB0403 Pooled analysis of 4 international trials of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in adults aged >65 or older demonstrating safety and efficacy: Week 48 resultsOral Abstract SessionB25
OAB0404 Third-line antiretroviral therapy including raltegravir, darunavir/ritonavir and/or etravirine is well tolerated and achieves durable virologic suppression over 144+ weeks in resource limited settings ACTG: A5288 strategy trialOral Abstract SessionB31
OAB0405 Sub-optimal outcomes with switching to zidovudine vs. recycling tenofovir in second-line treatment in HaitiOral Abstract SessionB30
OAB0502 Efficacy and safety outcomes (HIV subgroup analysis) in the Nix-TB Trial - bedaquiline, pretomanid and linezolid for treatment of extensively resistant, intolerant or non-responsive pulmonary multidrug-resistant tuberculosisOral Abstract SessionB10
seek-warrow-warrow-eseek-e81 - 90 of 2297 items